Stories

Axios Feb 15, 2017
SaveSave story

PhRMA throws shade at Marathon for big drug price hike

Pharmaceutical Research and Manufacturers of America, the main drug industry lobbying group, is distancing itself from Marathon Pharmaceuticals after the company announced an $89,000 price tag for an old drug that's newly approved to treat Duchenne muscular dystrophy.

In a statement Wednesday night, the group said it was "pleased" that Marathon put its U.S. rollout of the drug on hold, but it said the company's "recent actions are not consistent with the mission of our organization."

It added that "the leadership of the PhRMA Board of Directors has begun a comprehensive review of our membership criteria to ensure we are focused on representing research-based biopharmaceutical companies who take significant risks to bring new treatments and cures to patients."